25 XP   0   0   10

Caribou Biosciences Inc
Buy, Hold or Sell?

Let's analyse Caribou Biosciences Inc together

PenkeI guess you are interested in Caribou Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Caribou Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Caribou Biosciences Inc

I send you an email if I find something interesting about Caribou Biosciences Inc.

Quick analysis of Caribou Biosciences Inc (30 sec.)










What can you expect buying and holding a share of Caribou Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.08
Expected worth in 1 year
$4.83
How sure are you?
12.5%

+ What do you gain per year?

Total Gains per Share
$0.75
Return On Investment
18.8%

For what price can you sell your share?

Current Price per Share
$3.98
Expected price per share
$3.44 - $4.99
How sure are you?
50%

1. Valuation of Caribou Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)

$3.98

Intrinsic Value Per Share

$-14.35 - $-16.90

Total Value Per Share

$-10.27 - $-12.82

2. Growth of Caribou Biosciences Inc (5 min.)




Is Caribou Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$368.4m$336.1m-$7.5m-2.3%

How much money is Caribou Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$24.7m-$24m-$745.2k-3.0%
Net Profit Margin-627.9%-696.7%--

How much money comes from the company's main activities?

3. Financial Health of Caribou Biosciences Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#154 / 1009

Most Revenue
#306 / 1009

Most Profit
#742 / 1009

Most Efficient
#763 / 1009

What can you expect buying and holding a share of Caribou Biosciences Inc? (5 min.)

Welcome investor! Caribou Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Caribou Biosciences Inc.

What can you expect buying and holding a share of Caribou Biosciences Inc?

First you should know what it really means to hold a share of Caribou Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Caribou Biosciences Inc is $3.98. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Caribou Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Caribou Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.08. Based on the TTM, the Book Value Change Per Share is $0.19 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Caribou Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.38-9.6%-0.28-7.1%-0.28-6.9%-0.21-5.3%-0.21-5.3%
Usd Book Value Change Per Share-0.33-8.3%0.194.7%-0.24-6.0%0.256.4%0.256.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.33-8.3%0.194.7%-0.24-6.0%0.256.4%0.256.4%
Usd Price Per Share5.73-5.02-7.86-11.40-11.40-
Price to Earnings Ratio-3.75--5.52--7.41--25.36--25.36-
Price-to-Total Gains Ratio-17.33--19.69--34.18--48.73--48.73-
Price to Book Ratio1.40-1.41-2.12--7.51--7.51-
Price-to-Total Gains Ratio-17.33--19.69--34.18--48.73--48.73-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.98
Number of shares251
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.190.25
Usd Total Gains Per Share0.190.25
Gains per Quarter (251 shares)46.9263.99
Gains per Year (251 shares)187.68255.96
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101881780256246
203753660512502
305635540768758
40751742010241014
50938930012801270
6011261118015361526
7013141306017921782
8015011494020482038
9016891682023042294
10018771870025602550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.016.00.00.0%0.016.00.00.0%0.016.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%2.011.03.012.5%2.011.03.012.5%2.011.03.012.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.016.00.0%0.00.016.00.0%0.00.016.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%2.011.03.012.5%2.011.03.012.5%2.011.03.012.5%

Fundamentals of Caribou Biosciences Inc

About Caribou Biosciences Inc

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Fundamental data was last updated by Penke on 2024-04-11 16:48:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Caribou Biosciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Caribou Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Caribou Biosciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -969.8% means that $-9.70 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Caribou Biosciences Inc:

  • The MRQ is -969.8%. The company is making a huge loss. -2
  • The TTM is -627.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-969.8%TTM-627.9%-341.9%
TTM-627.9%YOY-696.7%+68.8%
TTM-627.9%5Y-693.9%+65.9%
5Y-693.9%10Y-693.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-969.8%-200.1%-769.7%
TTM-627.9%-216.8%-411.1%
YOY-696.7%-288.3%-408.4%
5Y-693.9%-449.1%-244.8%
10Y-693.9%-605.5%-88.4%
1.1.2. Return on Assets

Shows how efficient Caribou Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Caribou Biosciences Inc to the Biotechnology industry mean.
  • -7.8% Return on Assets means that Caribou Biosciences Inc generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Caribou Biosciences Inc:

  • The MRQ is -7.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.8%TTM-6.4%-1.4%
TTM-6.4%YOY-5.9%-0.5%
TTM-6.4%5Y-7.2%+0.8%
5Y-7.2%10Y-7.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.8%-13.3%+5.5%
TTM-6.4%-12.8%+6.4%
YOY-5.9%-11.7%+5.8%
5Y-7.2%-13.9%+6.7%
10Y-7.2%-15.7%+8.5%
1.1.3. Return on Equity

Shows how efficient Caribou Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Caribou Biosciences Inc to the Biotechnology industry mean.
  • -9.4% Return on Equity means Caribou Biosciences Inc generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Caribou Biosciences Inc:

  • The MRQ is -9.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.4%TTM-8.0%-1.4%
TTM-8.0%YOY-7.3%-0.7%
TTM-8.0%5Y-4.4%-3.5%
5Y-4.4%10Y-4.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.4%-16.9%+7.5%
TTM-8.0%-16.1%+8.1%
YOY-7.3%-15.1%+7.8%
5Y-4.4%-19.3%+14.9%
10Y-4.4%-20.2%+15.8%

1.2. Operating Efficiency of Caribou Biosciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Caribou Biosciences Inc is operating .

  • Measures how much profit Caribou Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Caribou Biosciences Inc to the Biotechnology industry mean.
  • An Operating Margin of -1,052.3% means the company generated $-10.52  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Caribou Biosciences Inc:

  • The MRQ is -1,052.3%. The company is operating very inefficient. -2
  • The TTM is -725.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,052.3%TTM-725.4%-326.9%
TTM-725.4%YOY-773.2%+47.7%
TTM-725.4%5Y-749.0%+23.5%
5Y-749.0%10Y-749.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,052.3%-296.2%-756.1%
TTM-725.4%-232.5%-492.9%
YOY-773.2%-298.2%-475.0%
5Y-749.0%-492.1%-256.9%
10Y-749.0%-632.4%-116.6%
1.2.2. Operating Ratio

Measures how efficient Caribou Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 11.52 means that the operating costs are $11.52 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Caribou Biosciences Inc:

  • The MRQ is 11.523. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.371. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ11.523TTM8.371+3.152
TTM8.371YOY8.925-0.554
TTM8.3715Y8.606-0.234
5Y8.60610Y8.6060.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.5233.231+8.292
TTM8.3713.310+5.061
YOY8.9253.890+5.035
5Y8.6065.739+2.867
10Y8.6067.876+0.730

1.3. Liquidity of Caribou Biosciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Caribou Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 11.97 means the company has $11.97 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Caribou Biosciences Inc:

  • The MRQ is 11.972. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.723. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.972TTM10.723+1.249
TTM10.723YOY11.484-0.760
TTM10.7235Y8.476+2.247
5Y8.47610Y8.4760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.9723.890+8.082
TTM10.7234.173+6.550
YOY11.4845.344+6.140
5Y8.4766.126+2.350
10Y8.4766.448+2.028
1.3.2. Quick Ratio

Measures if Caribou Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Caribou Biosciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 21.57 means the company can pay off $21.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Caribou Biosciences Inc:

  • The MRQ is 21.566. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 18.606. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ21.566TTM18.606+2.960
TTM18.606YOY19.237-0.631
TTM18.6065Y12.751+5.855
5Y12.75110Y12.7510.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.5663.514+18.052
TTM18.6063.998+14.608
YOY19.2375.380+13.857
5Y12.7516.105+6.646
10Y12.7516.404+6.347

1.4. Solvency of Caribou Biosciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Caribou Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Caribou Biosciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Caribou Biosciences Inc assets are financed with 16.5% credit (debt) and the remaining percentage (100% - 16.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Caribou Biosciences Inc:

  • The MRQ is 0.165. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.181. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.165TTM0.181-0.016
TTM0.181YOY0.1810.000
TTM0.1815Y0.366-0.185
5Y0.36610Y0.3660.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1650.339-0.174
TTM0.1810.336-0.155
YOY0.1810.271-0.090
5Y0.3660.366+0.000
10Y0.3660.389-0.023
1.4.2. Debt to Equity Ratio

Measures if Caribou Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Caribou Biosciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 19.7% means that company has $0.20 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Caribou Biosciences Inc:

  • The MRQ is 0.197. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.223. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.197TTM0.223-0.026
TTM0.223YOY0.221+0.002
TTM0.2235Y0.129+0.094
5Y0.12910Y0.1290.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1970.388-0.191
TTM0.2230.402-0.179
YOY0.2210.335-0.114
5Y0.1290.426-0.297
10Y0.1290.461-0.332

2. Market Valuation of Caribou Biosciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Caribou Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Caribou Biosciences Inc to the Biotechnology industry mean.
  • A PE ratio of -3.75 means the investor is paying $-3.75 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Caribou Biosciences Inc:

  • The EOD is -2.604. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.749. Based on the earnings, the company is expensive. -2
  • The TTM is -5.516. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.604MRQ-3.749+1.145
MRQ-3.749TTM-5.516+1.767
TTM-5.516YOY-7.411+1.895
TTM-5.5165Y-25.362+19.846
5Y-25.36210Y-25.3620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.604-2.264-0.340
MRQ-3.749-2.629-1.120
TTM-5.516-2.680-2.836
YOY-7.411-4.145-3.266
5Y-25.362-6.257-19.105
10Y-25.362-6.254-19.108
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Caribou Biosciences Inc:

  • The EOD is -3.799. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.469. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.524. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.799MRQ-5.469+1.670
MRQ-5.469TTM-4.524-0.945
TTM-4.524YOY-7.351+2.827
TTM-4.5245Y-15.396+10.872
5Y-15.39610Y-15.3960.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.799-2.973-0.826
MRQ-5.469-3.333-2.136
TTM-4.524-3.553-0.971
YOY-7.351-5.605-1.746
5Y-15.396-8.376-7.020
10Y-15.396-8.865-6.531
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Caribou Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.40 means the investor is paying $1.40 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Caribou Biosciences Inc:

  • The EOD is 0.976. Based on the equity, the company is cheap. +2
  • The MRQ is 1.405. Based on the equity, the company is underpriced. +1
  • The TTM is 1.409. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.976MRQ1.405-0.429
MRQ1.405TTM1.409-0.004
TTM1.409YOY2.116-0.707
TTM1.4095Y-7.511+8.921
5Y-7.51110Y-7.5110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9761.896-0.920
MRQ1.4052.115-0.710
TTM1.4092.093-0.684
YOY2.1162.884-0.768
5Y-7.5113.542-11.053
10Y-7.5113.916-11.427
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Caribou Biosciences Inc.

3.1. Institutions holding Caribou Biosciences Inc

Institutions are holding 80.332% of the shares of Caribou Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc7.82650.001706846898402816.1729
2023-09-30Partner Fund Management LP7.44591.51426724715115384620.7121
2023-12-31Avidity Partners Management LP7.04231.328263602123100005.1238
2023-12-31State Street Corporation5.66870.00145119666-233723-4.3659
2023-12-31Vanguard Group Inc4.38690.000539620441398933.6601
2023-09-30Deerfield Management Co3.87530.3686350000035000000
2023-09-30Point72 Asset Management, L.P.3.87520.0488349983332100941107.9261
2023-12-31Alkeon Capital Management, LLC3.44750.03983113564146870189.2902
2023-12-31Paradigm Biocapital Advisors LP3.23740.78442923851-20662-0.7017
2023-12-31Elmwood Wealth Management, Inc.2.61789.50272364260-155-0.0066
2023-12-31Assenagon Asset Management SA2.50070.03442258539-390043-14.7265
2023-12-31Geode Capital Management, LLC1.98710.0011179464821750713.7912
2023-12-31Bank of America Corp1.7640.00091593136-713662-30.9373
2023-12-31FMR Inc1.59950.00061444576-619-0.0428
2023-12-31Dimensional Fund Advisors, Inc.1.49560.00231350784757107127.5284
2023-12-31Goldman Sachs Group Inc1.46160.00071320080924471233.683
2023-12-31Woodline Partners LP1.2630.07111140671679133147.1456
2023-12-31Morgan Stanley - Brokerage Accounts1.22330.00061104813-712866-39.2185
2023-12-31Kynam Capital Management, LP1.18310.6783106852700
2023-12-31Pictet Asset Manangement SA1.04180.006940911-988478-51.2327
Total 64.943214.385658653298+10284572+17.5%

3.2. Funds holding Caribou Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF4.99480.30714511049569201.2779
2024-02-29Vanguard Total Stock Mkt Idx Inv2.59010.0012233926700
2024-03-28iShares Russell 2000 ETF2.22880.015820129259720.0483
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.33360.00931204398150551.2658
2024-02-29Belfius Equities Cure C Cap1.26780.4795114500020500021.8085
2023-12-31Candriam Global Equities Oncology0.95220.265486000036000072
2024-01-31Fidelity Small Cap Index0.9170.0205828162112461.3766
2024-03-28iShares Russell 2000 Value ETF0.85550.0317772603-490-0.0634
2024-03-31Selectra J. Lamarck Biotech A0.83853.6582757300229003.1182
2023-12-31Pictet-Global Megatrend Sel I USD0.74490.030767274913790.2054
2024-03-28iShares Biotechnology ETF0.65330.039859006600
2024-03-31Direxion Daily S&P Biotech Bull 3X ETF0.59950.2229541449-3798-0.6966
2024-02-29JPM Thematics Genetic Thrps C2 Acc USD0.5510.4903497642-7529-1.4904
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.53260.009148099229000.6066
2024-02-29Fidelity Extended Market Index0.52780.0098476702168913.6735
2024-03-29Schwab US Small-Cap ETF™0.42890.011738735000
2024-02-29DFA US Micro Cap I0.41740.041637694700
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.3450.016431158000
2024-02-29DFA US Small Cap I0.33230.0153300130170176.0107
2024-02-29Vanguard Russell 2000 ETF0.32970.0247297809233978.5262
Total 21.44075.70119364120+721860+3.7%

3.3. Insider Transactions

Insiders are holding 12.422% of the shares of Caribou Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-01-19Syed Ali-aamir RizviSELL56276.31
2022-10-06Ryan FischesserSELL1000010.8
2022-08-25Steven KannerSELL4324811.22
2022-01-11Ryan FischesserBUY73874
2021-12-20Ryan FischesserBUY11362.69
2021-12-07Barbara G McclungBUY61272.69
2021-10-20Barbara G McclungBUY92192.69
2021-10-12Steven KannerBUY1148601.92
2021-10-11Ryan FischesserBUY17462.69

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Caribou Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3310.187-277%-0.241-27%0.255-230%0.255-230%
Book Value Per Share--4.0793.638+12%3.722+10%2.314+76%2.314+76%
Current Ratio--11.97210.723+12%11.484+4%8.476+41%8.476+41%
Debt To Asset Ratio--0.1650.181-9%0.181-9%0.366-55%0.366-55%
Debt To Equity Ratio--0.1970.223-12%0.221-11%0.129+53%0.129+53%
Dividend Per Share----0%-0%-0%-0%
Eps---0.382-0.283-26%-0.275-28%-0.209-45%-0.209-45%
Free Cash Flow Per Share---0.262-0.290+11%-0.271+4%-0.189-28%-0.189-28%
Free Cash Flow To Equity Per Share---0.2620.137-292%-0.265+1%0.220-219%0.220-219%
Gross Profit Margin--0.9430.986-4%1.000-6%0.996-5%0.996-5%
Intrinsic Value_10Y_max---16.902--------
Intrinsic Value_10Y_min---14.349--------
Intrinsic Value_1Y_max---1.000--------
Intrinsic Value_1Y_min---0.981--------
Intrinsic Value_3Y_max---3.532--------
Intrinsic Value_3Y_min---3.362--------
Intrinsic Value_5Y_max---6.703--------
Intrinsic Value_5Y_min---6.176--------
Market Cap359451694.080-44%517502062.080453152983.680+14%709871938.560-27%1029677262.293-50%1029677262.293-50%
Net Profit Margin---9.698-6.279-35%-6.967-28%-6.939-28%-6.939-28%
Operating Margin---10.523-7.254-31%-7.732-27%-7.490-29%-7.490-29%
Operating Ratio--11.5238.371+38%8.925+29%8.606+34%8.606+34%
Pb Ratio0.976-44%1.4051.4090%2.116-34%-7.511+635%-7.511+635%
Pe Ratio-2.604+31%-3.749-5.516+47%-7.411+98%-25.362+576%-25.362+576%
Price Per Share3.980-44%5.7305.018+14%7.860-27%11.401-50%11.401-50%
Price To Free Cash Flow Ratio-3.799+31%-5.469-4.524-17%-7.351+34%-15.396+182%-15.396+182%
Price To Total Gains Ratio-12.035+31%-17.327-19.686+14%-34.180+97%-48.728+181%-48.728+181%
Quick Ratio--21.56618.606+16%19.237+12%12.751+69%12.751+69%
Return On Assets---0.078-0.064-18%-0.059-24%-0.072-8%-0.072-8%
Return On Equity---0.094-0.080-15%-0.073-22%-0.044-53%-0.044-53%
Total Gains Per Share---0.3310.187-277%-0.241-27%0.255-230%0.255-230%
Usd Book Value--368401000.000328599750.000+12%336167750.000+10%209029937.500+76%209029937.500+76%
Usd Book Value Change Per Share---0.3310.187-277%-0.241-27%0.255-230%0.255-230%
Usd Book Value Per Share--4.0793.638+12%3.722+10%2.314+76%2.314+76%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.382-0.283-26%-0.275-28%-0.209-45%-0.209-45%
Usd Free Cash Flow---23656000.000-26226000.000+11%-24505000.000+4%-17068375.000-28%-17068375.000-28%
Usd Free Cash Flow Per Share---0.262-0.290+11%-0.271+4%-0.189-28%-0.189-28%
Usd Free Cash Flow To Equity Per Share---0.2620.137-292%-0.265+1%0.220-219%0.220-219%
Usd Market Cap359451694.080-44%517502062.080453152983.680+14%709871938.560-27%1029677262.293-50%1029677262.293-50%
Usd Price Per Share3.980-44%5.7305.018+14%7.860-27%11.401-50%11.401-50%
Usd Profit---34505000.000-24753250.000-28%-24008000.000-30%-18517250.000-46%-18517250.000-46%
Usd Revenue--3558000.0008619250.000-59%3462750.000+3%4392937.500-19%4392937.500-19%
Usd Total Gains Per Share---0.3310.187-277%-0.241-27%0.255-230%0.255-230%
 EOD+3 -5MRQTTM+16 -18YOY+16 -185Y+8 -2610Y+8 -26

4.2. Fundamental Score

Let's check the fundamental score of Caribou Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.604
Price to Book Ratio (EOD)Between0-10.976
Net Profit Margin (MRQ)Greater than0-9.698
Operating Margin (MRQ)Greater than0-10.523
Quick Ratio (MRQ)Greater than121.566
Current Ratio (MRQ)Greater than111.972
Debt to Asset Ratio (MRQ)Less than10.165
Debt to Equity Ratio (MRQ)Less than10.197
Return on Equity (MRQ)Greater than0.15-0.094
Return on Assets (MRQ)Greater than0.05-0.078
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Caribou Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4.000
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -1,518788-730-406-1,136155-9811,01130



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets440,968
Total Liabilities72,567
Total Stockholder Equity368,401
 As reported
Total Liabilities 72,567
Total Stockholder Equity+ 368,401
Total Assets = 440,968

Assets

Total Assets440,968
Total Current Assets338,841
Long-term Assets102,127
Total Current Assets
Cash And Cash Equivalents 51,162
Short-term Investments 277,665
Net Receivables 3,859
Other Current Assets 6,155
Total Current Assets  (as reported)338,841
Total Current Assets  (calculated)338,841
+/-0
Long-term Assets
Property Plant Equipment 40,452
Long Term Investments 51,330
Long-term Assets Other 1,586
Long-term Assets  (as reported)102,127
Long-term Assets  (calculated)93,368
+/- 8,759

Liabilities & Shareholders' Equity

Total Current Liabilities28,302
Long-term Liabilities44,265
Total Stockholder Equity368,401
Total Current Liabilities
Short-term Debt 1,577
Accounts payable 3,120
Other Current Liabilities 20,758
Total Current Liabilities  (as reported)28,302
Total Current Liabilities  (calculated)25,455
+/- 2,847
Long-term Liabilities
Capital Lease Obligations 27,108
Long-term Liabilities Other 2,939
Long-term Liabilities  (as reported)44,265
Long-term Liabilities  (calculated)30,047
+/- 14,218
Total Stockholder Equity
Common Stock8
Retained Earnings -299,285
Accumulated Other Comprehensive Income 30
Other Stockholders Equity 667,648
Total Stockholder Equity (as reported)368,401
Total Stockholder Equity (calculated)368,401
+/-0
Other
Capital Stock8
Cash and Short Term Investments 328,827
Common Stock Shares Outstanding 88,433
Current Deferred Revenue2,847
Liabilities and Stockholders Equity 440,968
Net Debt -23,677
Net Invested Capital 368,401
Net Working Capital 310,539
Property Plant and Equipment Gross 49,596
Short Long Term Debt Total 27,485



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
36,046
167,965
158,397
461,960
442,356
445,997
421,367
398,823
373,765
347,462
349,647
457,521
440,968
440,968457,521349,647347,462373,765398,823421,367445,997442,356461,960158,397167,96536,046000
   > Total Current Assets 
0
0
0
24,306
155,925
142,967
449,047
391,192
368,010
352,928
306,922
260,248
239,490
268,538
350,693
338,841
338,841350,693268,538239,490260,248306,922352,928368,010391,192449,047142,967155,92524,306000
       Cash And Cash Equivalents 
0
0
0
15,953
145,924
129,524
435,310
240,420
147,630
112,146
82,085
58,338
52,744
66,194
104,058
51,162
51,162104,05866,19452,74458,33882,085112,146147,630240,420435,310129,524145,92415,953000
       Short-term Investments 
0
0
0
0
0
7,626
0
135,412
206,101
227,778
211,284
189,325
175,794
193,038
234,430
277,665
277,665234,430193,038175,794189,325211,284227,778206,101135,41207,62600000
       Net Receivables 
0
0
0
5,160
5,825
8,407
7,785
8,124
6,037
5,711
4,995
4,664
4,842
3,742
5,136
3,859
3,8595,1363,7424,8424,6644,9955,7116,0378,1247,7858,4075,8255,160000
       Other Current Assets 
0
0
0
760
1,080
1,277
763
671
966
1,410
1,103
1,119
1,234
1,485
1,611
6,155
6,1551,6111,4851,2341,1191,1031,4109666717631,2771,080760000
   > Long-term Assets 
0
0
0
11,740
12,040
15,430
12,913
51,164
77,987
68,439
91,901
113,517
107,972
81,109
106,828
102,127
102,127106,82881,109107,972113,51791,90168,43977,98751,16412,91315,43012,04011,740000
       Property Plant Equipment 
0
0
0
3,502
3,380
4,408
4,477
4,887
31,765
33,256
33,585
34,908
36,361
38,635
39,278
40,452
40,45239,27838,63536,36134,90833,58533,25631,7654,8874,4774,4083,3803,502000
       Long Term Investments 
0
0
0
7,626
7,626
7,626
7,626
45,302
44,758
33,880
56,980
77,071
70,135
41,055
65,982
51,330
51,33065,98241,05570,13577,07156,98033,88044,75845,3027,6267,6267,6267,626000
       Other Assets 
0
0
0
0
1,034
3,396
810
975
1,464
1,303
1,336
1,538
0
1,419
0
0
001,41901,5381,3361,3031,4649758103,3961,0340000
> Total Liabilities 
0
0
0
59,483
203,654
206,088
57,559
54,531
74,200
73,478
74,709
72,894
69,190
80,189
59,253
72,567
72,56759,25380,18969,19072,89474,70973,47874,20054,53157,559206,088203,65459,483000
   > Total Current Liabilities 
0
0
0
12,389
22,210
26,007
26,158
25,829
26,667
28,855
28,814
28,128
27,100
34,375
24,572
28,302
28,30224,57234,37527,10028,12828,81428,85526,66725,82926,15826,00722,21012,389000
       Short-term Debt 
0
0
0
654
655
559
13,159
12,348
825
877
912
966
1,022
1,079
1,139
1,577
1,5771,1391,0791,02296691287782512,34813,159559655654000
       Short Long Term Debt 
0
0
0
654
1,220
559
0
0
0
0
0
0
0
0
0
0
00000000005591,220654000
       Accounts payable 
0
0
0
2,601
3,117
4,029
3,482
3,990
1,814
426
1,228
1,146
2,651
4,433
2,377
3,120
3,1202,3774,4332,6511,1461,2284261,8143,9903,4824,0293,1172,601000
       Other Current Liabilities 
0
0
0
8,973
13,163
12,738
771
788
11,190
14,910
14,638
16,079
12,544
15,901
18,230
20,758
20,75818,23015,90112,54416,07914,63814,91011,19078877112,73813,1638,973000
   > Long-term Liabilities 
0
0
0
47,094
181,444
180,081
31,401
28,702
47,533
44,623
45,895
44,766
42,090
45,814
34,681
44,265
44,26534,68145,81442,09044,76645,89544,62347,53328,70231,401180,081181,44447,094000
       Other Liabilities 
0
0
0
0
30,368
29,931
31,401
28,702
20,295
17,533
18,937
17,986
0
19,659
0
0
0019,659017,98618,93717,53320,29528,70231,40129,93130,3680000
       Deferred Long Term Liability 
0
0
0
0
0
25,933
25,010
24,605
17,802
16,101
475
0
382
380
0
0
00380382047516,10117,80224,60525,01025,93300000
> Total Stockholder Equity
0
0
0
-23,437
-35,689
-47,691
404,401
387,825
371,797
347,889
324,114
300,871
278,272
269,458
398,268
368,401
368,401398,268269,458278,272300,871324,114347,889371,797387,825404,401-47,691-35,689-23,437000
   Common Stock
0
0
0
1
1
1
6
6
6
6
6
6
6
6
8
8
8866666666111000
   Retained Earnings Total Equity00-254,778-225,259-197,215-170,226-143,579-116,882-97,794-79,315-58,34100000
   Accumulated Other Comprehensive Income 
0
0
0
0
-3,315
-150,150
-461,960
-135
-1,089
-1,581
-2,035
-1,518
-730
-1,136
-981
30
30-981-1,136-730-1,518-2,035-1,581-1,089-135-461,960-150,150-3,3150000
   Capital Surplus 
0
0
0
0
0
10,649
483,710
485,748
489,762
493,043
496,369
499,598
504,255
525,366
0
0
00525,366504,255499,598496,369493,043489,762485,748483,71010,64900000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
-33,890
-138,495
10,649
483,710
485,748
489,762
493,043
496,369
499,598
504,255
525,366
664,021
667,648
667,648664,021525,366504,255499,598496,369493,043489,762485,748483,71010,649-138,495-33,890000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue34,477
Cost of Revenue-3,525
Gross Profit30,95230,952
 
Operating Income (+$)
Gross Profit30,952
Operating Expense-147,011
Operating Income-116,059-116,059
 
Operating Expense (+$)
Research Development112,075
Selling General Administrative38,461
Selling And Marketing Expenses-3,525
Operating Expense147,011147,011
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-116,059
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-101,877-130,241
EBIT - interestExpense = -116,059
-101,877
-102,070
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-116,059-101,877
Earnings Before Interest and Taxes (EBITDA)-112,534
 
After tax Income (+$)
Income Before Tax-101,877
Tax Provision-193
Net Income From Continuing Ops-94,554-102,070
Net Income-102,070
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses150,536
Total Other Income/Expenses Net14,1820
 

Technical Analysis of Caribou Biosciences Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Caribou Biosciences Inc. The general trend of Caribou Biosciences Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Caribou Biosciences Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Caribou Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.69 < 4.99 < 4.99.

The bearish price targets are: 3.7 > 3.44.

Tweet this
Caribou Biosciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Caribou Biosciences Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Caribou Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartCaribou Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Caribou Biosciences Inc. The current adx is .

Caribou Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Relative Strength Index (RSI) ChartCaribou Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Stochastic Oscillator ChartCaribou Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Commodity Channel Index (CCI) ChartCaribou Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartCaribou Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Williams %R ChartCaribou Biosciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Average True Range (ATR) ChartCaribou Biosciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily On-Balance Volume (OBV) ChartCaribou Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Caribou Biosciences Inc.

Caribou Biosciences Inc Daily Money Flow Index (MFI) ChartCaribou Biosciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Caribou Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

Caribou Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Caribou Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4.000
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Caribou Biosciences Inc with someone you think should read this too:
  • Are you bullish or bearish on Caribou Biosciences Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Caribou Biosciences Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Caribou Biosciences Inc

I send you an email if I find something interesting about Caribou Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Caribou Biosciences Inc.

Receive notifications about Caribou Biosciences Inc in your mailbox!